Chemoprophylaxis of precancerous lesions in patients who are at a high risk of developing colorectal cancer (Review)
- Authors:
- Nonna E. Ogurchenok
- Konstantin D. Khalin
- Igor S. Bryukhovetskiy
-
Affiliations: Far Eastern Federal University, School of Medicine and Life Sciences, FEFU Medical Center, Russky Island, 690091 Vladivostok, Russian Federation, Far Eastern Federal University, Medical Center, Russky Island, 690091 Vladivostok, Russian Federation - Published online on: March 27, 2024 https://doi.org/10.3892/mi.2024.149
- Article Number: 25
-
Copyright : © Ogurchenok et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
This article is mentioned in:
Abstract
 |
 |
 |
|
Li S, Keenan JI, Shaw IC and Frizelle FA: Could microplastics be a driver for early onset colorectal cancer? Cancers (Basel). 15(3323)2023.PubMed/NCBI View Article : Google Scholar | |
|
Matich EK, Laryea JA, Seely KA, Stahr S, Su LJ and Hsu PC: Association between pesticide exposure and colorectal cancer risk and incidence: A systematic review. Ecotoxicol Environ Saf. 219(112327)2021.PubMed/NCBI View Article : Google Scholar | |
|
Pritchett N, Spangler EC, Gray GM, Livinski AA, Sampson JN, Dawsey SM and Jones RR: Exposure to outdoor particulate matter air pollution and risk of gastrointestinal cancers in adults: A Systematic review and meta-analysis of epidemiologic evidence. Environ Health Perspect. 130(36001)2022.PubMed/NCBI View Article : Google Scholar | |
|
Picetti R, Deeney M, Pastorino S, Miller MR, Shah A, Leon DA, Dangour AD and Green R: Nitrate and nitrite contamination in drinking water and cancer risk: A systematic review with meta-analysis. Environ Res. 210(112988)2022.PubMed/NCBI View Article : Google Scholar | |
|
González N, Marquès M, Nadal M and Domingo JL: Meat consumption: Which are the current global risks? A review of recent (2010-2020) evidences. Food Res Int. 137(109341)2020.PubMed/NCBI View Article : Google Scholar | |
|
García-Pérez J, Fernández de Larrea-Baz N, Lope V, Molina AJ, O'Callaghan-Gordo C, Alonso MH, Rodríguez-Suárez MM, Mirón-Pozo B, Alguacil J, Gómez-Acebo I, et al: Residential proximity to industrial pollution sources and colorectal cancer risk: A multicase-control study (MCC-Spain). Environ Int. 144(106055)2020.PubMed/NCBI View Article : Google Scholar | |
|
Lotfollahzadeh S, Recio-Boiles A and Cagir B: Colon cancer. In: StatPearls [Internet].StatPearls Publishing, Treasure Island, FL, 2023. | |
|
US Preventive Services Task Force. Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM, Donahue KE, Doubeni CA, Krist AH, et al: Screening for colorectal cancer: US Preventive services task force recommendation statement. JAMA. 325:1965–1977. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Kahi CJ, Hewett DG, Norton DL, Eckert GJ and Rex DK: Prevalence and variable detection of proximal colon serrated polyps during screening colonoscopy. Clin Gastroenterol Hepatol. 9:42–46. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Steele SR, Johnson EK, Champagne B, Davis B, Lee S, Rivadeneira D, Ross H, Hayden DA and Maykel JA: Endoscopy and polyps-diagnostic and therapeutic advances in management. World J Gastroenterol. 19:4277–4288. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, Andreu M, Carballo F, Morillas JD, Hernández C, et al: Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 366:697–706. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: . Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Li P, Li S, Chen J, Shao L, Lu X and Cai J: Association between family history and prognosis of patients with colorectal cancer: A systematic review and meta-analysis. Transl Cancer Res. 11:124–133. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Wautier JL and Wautier MP: Old and new blood markers in human colorectal cancer. Int J Mol Sci. 23(12968)2022.PubMed/NCBI View Article : Google Scholar | |
|
Siegel RL, Fedewa SA, Anderson WF, Miller KD, Ma J, Rosenberg PS and Jemal A: Colorectal cancer incidence patterns in the United States, 1974-2013. J Natl Cancer Inst. 109(djw322)2017.PubMed/NCBI View Article : Google Scholar | |
|
Doubeni CA, Corley DA, Quinn VP, Jensen CD, Zauber AG, Goodman M, Johnson JR, Mehta SJ, Becerra TA, Zhao WK, et al: Effectiveness of screening colonoscopy in reducing the risk of death from right and left colon cancer: A large community-based study. Gut. 67:291–298. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Cappell MS: The pathophysiology, clinical presentation, and diagnosis of colon cancer and adenomatous polyps. Med Clin North Am. 89:1–42, vii. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F and Cree IA: WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. Histopathology. 76:182–188. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Shah SC and Itzkowitz SH: Colorectal cancer in inflammatory bowel disease: Mechanisms and management. Gastroenterology. 162:715–730.e3. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Jung G, Hernández-Illán E, Moreira L, Balaguer F and Goel A: Epigenetics of colorectal cancer: Biomarker and therapeutic potential. Nature reviews. Nat Rev Gastroenterol Hepatol. 17:111–130. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Lao VV and Grady WM: Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol. 8:686–700. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Cervena K, Siskova A, Buchler T, Vodicka P and Vymetalkova V: Methylation-Based therapies for colorectal cancer. Cells. 9(1540)2020.PubMed/NCBI View Article : Google Scholar | |
|
Jass JR, Baker K, Zlobec I, Higuchi T, Barker M, Buchanan D and Young J: Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: Concept of a ‘fusion’ pathway to colorectal cancer. Histopathology. 49:121–131. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Ogino S, Kawasaki T, Kirkner GJ, Suemoto Y, Meyerhardt JA and Fuchs CS: Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Gut. 56:1564–1571. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Weisenberger DJ, Levine AJ, Long TI, Buchanan DD, Walters R, Clendenning M, Rosty C, Joshi AD, Stern MC, LeMarchand L, et al: Association of the colorectal CpG island methylator phenotype with molecular features, risk factors, and family history. Cancer Epidemiol Biomarkers Prev. 24:512–519. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Imperiale TF, Ransohoff DF and Itzkowitz SH: Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 371:187–188. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Kadiyska T and Nossikoff A: Stool DNA methylation assays in colorectal cancer screening. World J Gastroenterol. 21:10057–10061. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Tahara T, Yamamoto E, Madireddi P, Suzuki H, Maruyama R, Chung W, Garriga J, Jelinek J, Yamano HO, Sugai T, et al: Colorectal carcinomas with CpG island methylator phenotype 1 frequently contain mutations in chromatin regulators. Gastroenterology. 146:530–538.e5. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB and Issa JP: CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA. 96:8681–8686. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, et al: CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 38:787–793. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Snover DC: Update on the serrated pathway to colorectal carcinoma. Hum Pathol. 42:1–10. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Nakanishi Y, Diaz-Meco MT and Moscat J: Serrated colorectal cancer: The road less travelled? Trends Cancer. 5:742–754. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Missiaglia E, Jacobs B, D'Ario G, Di Narzo AF, Soneson C, Budinska E, Popovici V, Vecchione L, Gerster S, Yan P, et al: Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 25:1995–2001. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O and Desai J: Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 117:4623–4632. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Pino MS and Chung DC: The chromosomal instability pathway in colon cancer. Gastroenterology. 138:2059–2072. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Lengauer C, Kinzler KW and Vogelstein B: Genetic instabilities in human cancers. Nature. 396:643–649. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes. Science. 339:1546–1558. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Grady WM and Carethers JM: Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 135:1079–1099. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Jass JR, Whitehall VL, Young J and Leggett BA: Emerging concepts in colorectal neoplasia. Gastroenterology. 123:862–876. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Fodde R, Kuipers J, Rosenberg C, Smits R, Kielman M, Gaspar C, van Es JH, Breukel C, Wiegant J, Giles RH and Clevers H: Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat Cell Biol. 3:433–438. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Sparks AB, Morin PJ, Vogelstein B and Kinzler KW: Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 58:1130–1134. 1998.PubMed/NCBI | |
|
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al: Futreal. Mutations of the BRAF gene in human cancer. Nature. 417:949–954. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Jass JR: Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 50:113–130. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Rex DK, Ahnen DJ, Baron JA, Batts KP, Burke CA, Burt RW, Goldblum JR, Guillem JG, Kahi CJ, Kalady MF, et al: Serrated lesions of the colorectum: Review and recommendations from an expert panel. Am J Gastroenterol. 107:1315–1329; quiz 1314, 1330. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Zygulska AL and Pierzchalski P: Novel diagnostic biomarkers in colorectal cancer. Int J Mol Sci. 23(852)2022.PubMed/NCBI View Article : Google Scholar | |
|
Zhong J, Ding S, Zhang X, Di W, Wang X, Zhang H, Chen Y, Zhang Y and Hu Y: To investigate the occurrence and development of colorectal cancer based on the PI3K/AKT/mTOR signaling pathway. Front Biosci (Landmark Ed). 28(37)2023.PubMed/NCBI View Article : Google Scholar | |
|
Nusse R and Clevers H: Wnt/β-Catenin signaling, disease, and emerging therapeutic modalities. Cell. 169:985–999. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Vermeulen L, De Sousa E, Melo F, van der Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H, et al: Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. 12:468–476. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Söreide K, Janssen EA, Söiland H, Körner H and Baak JP: Microsatellite instability in colorectal cancer. Br J Surg. 93:395–406. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Odoux C, Fohrer H, Hoppo T, Guzik L, Stolz DB, Lewis DW, Gollin SM, Gamblin TC, Geller DA and Lagasse E: A stochastic model for cancer stem cell origin in metastatic colon cancer. Cancer Res. 68:6932–6941. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al: Mutational landscape and significance across 12 major cancer types. Nature. 502:333–339. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Jaiswal S: Clonal hematopoiesis and nonhematologic disorders. Blood. 136:1606–1614. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Jaiswal S and Ebert BL: Clonal hematopoiesis in human aging and disease. Science. 366(eaan4673)2019.PubMed/NCBI View Article : Google Scholar | |
|
Haggar FA and Boushey RP: Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 22:191–197. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu SC, Kim SS, et al: Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. Nat Med. 21:71–75. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Kosianova А, Pak O and Bryukhovetskiy I: Regulation of cancer stem cells and immunotherapy of glioblastoma (Review). Biomed Rep. 20(24)2023.PubMed/NCBI View Article : Google Scholar | |
|
Bryukhovetskiy I, Kosianova A, Zaitsev S, Pak O, Sharma A and Sharma HS: Glioblastoma: What can we do for these patients today and what will we be able to do in the future? Prog Brain Res. 265:99–118. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Pinczowski D, Ekbom A, Baron J, Yuen J and Adami HO: Risk factors for colorectal cancer in patients with ulcerative colitis: A case-control study. Gastroenterology. 107:117–120. 1994.PubMed/NCBI View Article : Google Scholar | |
|
Qiu X, Ma J, Wang K and Zhang H: Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: A systematic review with meta-analysis. Oncotarget. 8:1031–1045. 2017.PubMed/NCBI View Article : Google Scholar | |
|
OʼConnor A, Packey CD, Akbari M and Moss AC: Mesalamine, but not sulfasalazine, reduces the risk of colorectal neoplasia in patients with inflammatory bowel disease: An agent-specific systematic review and meta-analysis. Inflamm Bowel Dis. 21:2562–2569. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Lyakhovich A and Gasche C: Systematic review: Molecular chemoprevention of colorectal malignancy by mesalazine. Aliment Pharmacol Ther. 31:202–209. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Luciani MG, Campregher C, Fortune JM, Kunkel TA and Gasche C: 5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint. Gastroenterology. 132:221–235. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Gasche C, Goel A, Natarajan L and Boland CR: Mesalazine improves replication fidelity in cultured colorectal cells. Cancer Res. 65:3993–3997. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Nandi J, Saud B, Zinkievich JM, Palma DT and Levine RA: 5-aminosalicylic acid improves indomethacin-induced enteropathy by inhibiting iNOS transcription in rats. Dig Dis Sci. 53:123–132. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Monteleone G, Franchi L, Fina D, Caruso R, Vavassori P, Monteleone I, Calabrese E, Naccari GC, Bellinvia S, Testi R and Pallone F: Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells. Cell Death Differ. 13:202–211. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Chu EC, Chai J, Ahluwalia A and Tarnawski AS: Mesalazine downregulates c-Myc in human colon cancer cells. A key to its chemopreventive action? Aliment Pharmacol Ther. 25:1443–1449. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Bos CL, Diks SH, Hardwick JC, Walburg KV, Peppelenbosch MP and Richel DJ: Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. Carcinogenesis. 27:2371–2382. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Stolfi C, Pellegrini R, Franze E, Pallone F and Monteleone G: Molecular basis of the potential of mesalazine to prevent colorectal cancer. World J Gastroenterol. 14:4434–4439. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Song M, Xia B and Li J: Effects of topical treatment of sodium butyrate and 5-aminosalicylic acid on expression of trefoil factor 3, interleukin 1beta, and nuclear factor kappaB in trinitrobenzene sulphonic acid induced colitis in rats. Postgrad Med J. 82:130–135. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Bersuder E, Terciolo C, Lechevrel M, Martin E, Quesnelle C, Freund JN, Reimund JM and Gross I: Mesalazine initiates an anti-oncogenic β-catenin/MUCDHL negative feed-back loop in colon cancer cells by cell-specific mechanisms. Biomed Pharmacother. 146(112543)2022.PubMed/NCBI View Article : Google Scholar | |
|
Hall DCN and Benndorf RA: Aspirin sensitivity of PIK3CA-mutated colorectal cancer: Potential mechanisms revisited. Cell Mol Life Sci. 79(393)2022.PubMed/NCBI View Article : Google Scholar | |
|
Bosetti C, Santucci C, Gallus S, Martinetti M and La Vecchia C: Aspirin and the risk of colorectal and other digestive tract cancers: An updated meta-analysis through 2019. Ann Oncol. 31:558–568. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Ma J, Fan Z, Tang Q, Xia H, Zhang T and Bi F: Aspirin attenuates YAP and β-catenin expression by promoting β-TrCP to overcome docetaxel and vinorelbine resistance in triple-negative breast cancer. Cell Death Dis. 11(530)2020.PubMed/NCBI View Article : Google Scholar | |
|
Newman P and Muscat J: Potential role of non-steroidal anti-inflammatory drugs in colorectal cancer chemoprevention for inflammatory bowel disease: An umbrella review. Cancers (Basel). 15(1102)2023.PubMed/NCBI View Article : Google Scholar | |
|
Kohno H, Suzuki R, Sugie S and Tanaka T: Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer. 5(46)2005.PubMed/NCBI View Article : Google Scholar | |
|
Allgayer H and Kruis W: Aminosalicylates: Potential antineoplastic actions in colon cancer prevention. Scand J Gastroenterol. 37:125–131. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Hsiao SW, Yen HH and Chen YY: Chemoprevention of colitis-associated dysplasia or cancer in inflammatory bowel disease. Gut Liver. 16:840–848. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Kortüm B, Radhakrishnan H, Zincke F, Sachse C, Burock S, Keilholz U, Dahlmann M, Walther W, Dittmar G, Kobelt D and Stein U: Combinatorial treatment with statins and niclosamide prevents CRC dissemination by unhinging the MACC1-β-catenin-S100A4 axis of metastasis. Oncogene. 41:4446–4458. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Bassaganya-Riera J, Viladomiu M, Pedragosa M, De Simone C and Hontecillas R: Immunoregulatory mechanisms underlying prevention of colitis-associated colorectal cancer by probiotic bacteria. PLoS One. 7(e34676)2012.PubMed/NCBI View Article : Google Scholar | |
|
Strehl C, Ehlers L, Gaber T and Buttgereit F: Glucocorticoids-All-Rounders tackling the versatile players of the immune system. Front Immunol. 10(1744)2019.PubMed/NCBI View Article : Google Scholar | |
|
An YK: Common mistakes with steroids. J Gastroenterol Hepatol. 36 (Suppl 1):S30–S31. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, Langholff W, Londhe A and Sandborn WJ: Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol. 107:1409–1422. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Targownik LE, Nugent Z, Singh H and Bernstein CN: Prevalence of and outcomes associated with corticosteroid prescription in inflammatory bowel disease. Inflamm Bowel Dis. 20:622–630. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Melmed GY, Spiegel BM, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Irving PM, Jones J, Kaplan GG, Kozuch PL, et al: The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: One size does not fit all. Clin Gastroenterol Hepatol. 8:655–659. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Raine T and Kennedy NA: Immunomodulator and biologic combination therapy in IBD: The debate that just won't go away? J Crohns Colitis. 14:1343–1344. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Banerjee R, Ali RAR, Wei SC and Adsul S: Biologics for the management of inflammatory bowel disease: A review in tuberculosis-endemic countries. Gut Liver. 14:685–698. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Harris TA, Yamakuchi M, Ferlito M, Mendell JT and Lowenstein CJ: MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci USA. 105:1516–1521. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Neurath MF: Cytokines in inflammatory bowel disease. Nat Rev Immunol. 14:329–342. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Rutella S, Fiorino G, Vetrano S, Correale C, Spinelli A, Pagano N, Arena V, Maggiano N, Repici A, Malesci A and Danese S: Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn's disease. Am J Gastroenterol. 106:762–770. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Günther C, Martini E, Wittkopf N, Amann K, Weigmann B, Neumann H, Waldner MJ, Hedrick SM, Tenzer S, Neurath MF and Becker C: Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis. Nature. 477:335–339. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Van den Brande JM, Koehler TC, Zelinkova Z, Bennink RJ, te Velde AA, ten Cate FJ, van Deventer SJ, Peppelenbosch MP and Hommes DW: Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut. 56:509–517. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Chapman CG and Rubin DT: The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease. Gastrointest Endosc Clin N Am. 24:353–365. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Poutahidis T, Haigis KM, Rao VP, Nambiar PR, Taylor CL, Ge Z, Watanabe K, Davidson A, Horwitz BH, Fox JG and Erdman SE: Rapid reversal of interleukin-6-dependent epithelial invasion in a mouse model of microbially induced colon carcinoma. Carcinogenesis. 28:2614–2623. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Kim YJ, Hong KS, Chung JW, Kim JH and Hahm KB: Prevention of colitis-associated carcinogenesis with infliximab. Cancer Prev Res (Phila). 3:1314–1333. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S and Niezychowski W: Study A3921063 Investigators. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 367:616–624. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Beaugerie L, Svrcek M, Seksik P, Bouvier AM, Simon T, Allez M, Brixi H, Gornet JM, Altwegg R, Beau P, et al: Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 145:166–175.e8. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP, et al: Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: A prospective observational cohort study. Lancet. 374:1617–1625. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Zhu Z, Mei Z, Guo Y, Wang G, Wu T, Cui X, Huang Z, Zhu Y, Wen D, Song J, et al: Reduced risk of inflammatory bowel disease-associated colorectal neoplasia with use of thiopurines: A systematic review and meta-analysis. J Crohns Colitis. 12:546–558. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P, et al: Third European Evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 11:649–670. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Dobrzycka M, Spychalski P, Łachiński AJ, Kobiela P, Jędrusik P and Kobiela J: Statins and colorectal cancer-A systematic review. Exp Clin Endocrinol Diabetes. 128:255–262. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Carrat F, Seksik P, Colombel JF, Peyrin-Biroulet L and Beaugerie L: CESAME Study Group. The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 45:533–541. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Qi XF, Kim DH, Yoon YS, Kim SK, Cai DQ, Teng YC, Shim KY and Lee KJ: Involvement of oxidative stress in simvastatin-induced apoptosis of murine CT26 colon carcinoma cells. Toxicol Lett. 199:277–287. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Bergman M, Salman H, Djaldetti M and Bessler H: Statins as modulators of colon cancer cells induced cytokine secretion by human PBMC. Vascul Pharmacol. 54:88–92. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Ishikawa S, Hayashi H, Kinoshita K, Abe M, Kuroki H, Tokunaga R, Tomiyasu S, Tanaka H, Sugita H, Arita T, et al: Statins inhibit tumor progression via an enhancer of zeste homolog 2-mediated epigenetic alteration in colorectal cancer. Int J Cancer. 135:2528–2536. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Lim T, Lee I, Kim J and Kang WK: Synergistic effect of simvastatin plus radiation in gastric cancer and colorectal cancer: Implications of BIRC5 and connective tissue growth factor. Int J Radiat Oncol Biol Phys. 93:316–325. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Singh S, Edakkanambeth Varayil J, Loftus EV Jr and Talwalkar JA: Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: A systematic review and meta-analysis. Liver Transpl. 19:1361–1369. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Boonstra K, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BW, Poen AC, van Nieuwkerk KM, Drenth JP, Witteman BJ, Tuynman HA, et al: Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 58:2045–2055. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Singh S, Khanna S, Pardi DS, Loftus EV Jr and Talwalkar JA: Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: A systematic review and meta-analysis. Inflamm Bowel Dis. 19:1631–1638. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Nagengast FM, Grubben MJ and van Munster IP: Role of bile acids in colorectal carcinogenesis. Eur J Cancer. 31A:1067–1070. 1995.PubMed/NCBI View Article : Google Scholar | |
|
Potack J and Itzkowitz SH: Colorectal cancer in inflammatory bowel disease. Gut Liver. 2:61–73. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Swinson CM, Perry J, Lumb M and Levi AJ: Role of sulphasalazine in the aetiology of folate deficiency in ulcerative colitis. Gut. 22:456–461. 1981.PubMed/NCBI View Article : Google Scholar | |
|
Ditonno I, Novielli D, Celiberto F, Rizzi S, Rendina M, Ierardi E, Di Leo A and Losurdo G: Molecular pathways of carcinogenesis in familial adenomatous polyposis. Int J Mol Sci. 24(5687)2023.PubMed/NCBI View Article : Google Scholar | |
|
Mao R, Krautscheid P, Graham RP, Ganguly A, Shankar S, Ferber M and Hegde M: ACMG Laboratory Quality Assurance Committee. Genetic testing for inherited colorectal cancer and polyposis, 2021 revision: A technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 23:1807–1817. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Bhattacharya P and McHugh TW: Lynch Syndrome. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL, 2023. | |
|
Cohen PR and Kurzrock R: Germline testing of mismatch repair genes is needed in the initial evaluation of patients with muir-torre syndrome-associated cutaneous sebaceous neoplasms: A case series. Cureus. 15(e33975)2023.PubMed/NCBI View Article : Google Scholar | |
|
Park SY, Kim KS and Min HJ: Peutz-Jeghers syndrome and sinonasal diseases: A case report and literature review. Ear Nose Throat J: Sep 19, 2022 (Epub ahead of print). | |
|
Garofola C, Jamal Z and Gross GP: Cowden Disease. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL, 2023. | |
|
Dal Buono A, Gaiani F, Poliani L and Laghi L: Juvenile polyposis syndrome: An overview. Best Pract Res Clin Gastroenterol. 58-59(101799)2022.PubMed/NCBI View Article : Google Scholar | |
|
Soares de Lima Y, Arnau-Collell C, Muñoz J, Herrera-Pariente C, Moreira L, Ocaña T, Díaz-Gay M, Franch-Expósito S, Cuatrecasas M, Carballal S, et al: Germline mutations in WNK2 could be associated with serrated polyposis syndrome. J Med Genet. 60:557–567. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Ahmed M: Colon cancer: A clinician's perspective in 2019. Gastroenterology Res. 13:1–10. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Burnett-Hartman AN, Lee JK, Demb J and Gupta S: An update on the epidemiology, molecular characterization, diagnosis, and screening strategies for early-onset colorectal cancer. Gastroenterology. 160:1041–1049. 2021.PubMed/NCBI View Article : Google Scholar |
